The Effect of a Probiotic on Hepatic Steatosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00099723
Recruitment Status : Terminated (The hypothesis that probiotics would reduce hepatic steatosis in humans was not supported)
First Posted : December 20, 2004
Last Update Posted : February 11, 2010
Information provided by:
VSL Pharmaceuticals

Brief Summary:
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States. The exact cause of NAFLD is unknown, but it is more common among people with conditions such as adult-onset diabetes. NAFLD can strike people of all ages but most often affects adults between the ages of 40 and 60. Research indicates that overgrowth of gut bacteria can start a chain of biological processes that stress the liver, causing liver inflammation. Probiotics, living bacteria taken orally, may decrease the stress on the liver by reducing this bacterial overgrowth and/or strengthening the gut walls. Because probiotics are generally safe, inexpensive, and easy to tolerate they are an attractive treatment option for NAFLD.

Condition or disease Intervention/treatment Phase
Fatty Liver Drug: VSL#3 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Effect of a Probiotic on Hepatic Steatosis
Study Start Date : October 2004
Estimated Study Completion Date : December 2005

Primary Outcome Measures :
  1. MRI
  2. Liver biopsy
  3. Blood work

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult-onset diabetes
  • Liver biopsy in the previous 2 months with diagnosis of fatty liver and fibrosis stage F2-F3

Exclusion Criteria:

  • There are multiple exclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00099723

United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
VSL Pharmaceuticals
Principal Investigator: Steve Solga, MD Johns Hopkins University Identifier: NCT00099723     History of Changes
Other Study ID Numbers: SS01305-01
R21AT001305-01 ( U.S. NIH Grant/Contract )
First Posted: December 20, 2004    Key Record Dates
Last Update Posted: February 11, 2010
Last Verified: December 2004

Keywords provided by VSL Pharmaceuticals:
Hepatic steatosis
adult-onset diabetes
Non-alcoholic fatty liver disease

Additional relevant MeSH terms:
Fatty Liver
Liver Diseases
Digestive System Diseases